Extracted from this filing and checked against the source text.
Debt Financings
SEC 8-K Item 2.03/2.04
confidence 0.9
enGene Therapeutics Inc. amended term loan of up to $50 million with Hercules Capital, Inc. at greater of (a) the prime rate of interest as reported in the Wall Street Journal maturing January 1, 2028.
- Instrument
- term loan
- Principal
- up to $50 million
- Counterparty
- Hercules Capital, Inc.
- Rate
- greater of (a) the prime rate of interest as reported in the Wall Street Journal
- Maturity
- January 1, 2028
- Event
- amendment
Exact text from the filing
2021 (the “Prior Loan Agreement”), by, among other things, adding the Company as a co-borrower thereunder. The Amended Loan Agreement provides for a term loan facility of up to $50 million available in multiple tranches (the “Term Loan”), as follows: (i) an initial term loan advance (the “Tranche 1 Advance”) that was made on the Closing Date of $22.5 million,
View on SEC.gov
Material Agreements
SEC 8-K Item 1.01/1.02
confidence 0.9
enGene Therapeutics Inc. amended Amended and Restated Loan and Security Agreement with Hercules Capital, Inc. valued at up to $50 million (effective 2023-12-22).
- Action
- amendment
- Agreement
- credit facility
- Counterparty
- Hercules Capital, Inc.
- Value
- up to $50 million
- Effective
- 2023-12-22
Exact text from the filing
On December 22, 2023 (the “Closing Date”), enGene Holdings Inc. (the “Company”), together with its subsidiaries, enGene Inc. and enGene USA, Inc. (collectively with the Company, on a joint and several basis, the “Borrowers”) entered into an Amended and Restated Loan and Security Agreement (the “Amended Loan Agreement”), with Hercules Capital, Inc., as agent and lender (“Hercules” or “the Bank”), and the several banks and other financial institutions or entities from time to time parties thereto (with Hercules, the “Lenders”).
View on SEC.gov